KKR is still interested in buying Depomed, which has been up for sale, according to press reports. Final bids for Depomed, an opioid maker, are due Wednesday, the New York Post is reporting. Daichi Sankyo, of Japan, is also expected to bid, the story said. Depomed, of Newark, California, acquired Nucynta in early 2015 from Janssen Pharmaceuticals Inc for just over $1 billion, Reuters has reported.